|
INDEX
Note:
Just as this book is continually evolving, so is this
Index. It’s future development depends on you, and we welcome your input.
Send Us Your Comments
E-mail: womencare@hrsa.gov
Fax to the attention of “Womencare”: 301-443-0791 (USA)
Postal address: Womencare
Parklawn Building, Room 11A-33
5600 Fishers Lane
Rockville, Maryland 20857 USA
A A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Abacavir: 95, 100, 242
Abdominal pain, pelvic: 173, 358
differential diagnosis and management: 174, 358, 359
dysmenorrhea: 176
endometriosis: 176
evaluation: 174
gastrointestinal pathology: 177
medication-related: 177
mittelschmerz: 177
ovarian torsion: 176
pelvic inflammatory disease (PID): 174
indications for hospitalization in patients with PID: 176
PID in the HIV-positive woman: 175
ruptured/hemorrhagic ovarian cyst: 176
urinary tract pathology: 177
uterine leiomyomas (fibroids): 176
Abnormal Pap smear: 153
AGCUS (atypical glandular cells of undetermined significance): 157
ASCUS (atypical squamous cells of undetermined significance): 156
cervical dysplasia: 154
HIV and cervical dysplasia: 154
high-grade squamous intraepithelial lesion: 158
in management of abnormal Pap smear: 158
invasive carcinoma: 158
invasive cervical cancer in HIV disease: 154
low-grade squamous intraepithelial lesion: 158
management of cervical lesions: 158
recommendations for pap smear screening and colposcopy: 156
recommended management: 158
Abnormal uterine bleeding: 149
Abstinence: 41, 72, 340, 341, 342
Access to care: 39
Acute diarrhea: 126
Acute HIV infection, treatment of: 105
Acute infection, primary or: 13
Addiction severity index (ASI): 320
Adherence: 34, 35
and viral load: 140
children and adolescents: 143
improving: 144
in special populations: 142
incarcerated patients: 142
interventions, 145, 145
measuring: 143
nurse-based intervention to improve adherence: 146
patient factors associated with nonadherence: 141
predictors of: 140
reasons patients cite for missing medication: 142
to HIV therapies: 139
Adolescents: 335
abstinence and risk reduction: 340, 341, 342
adherence: using your EARS: 345
adolescent AIDS program, Montefiore Medical Center: 342
Adolescent Medicine HIV/AIDS Research Network (AMHARN): 343, 344
alcohol: 337
behavioral/biological risk: 337
clinical and psychosocial care: 343
condom use, factors associated with: 341, 342
confidentiality and legal issues: 338
counseling and testing,: 339
"one-shot" approach to counseling: 339
epidemiology: 335
heightened vulnerability for infection: 337
HIV care for adolescents: 338
HIV treatment: 344
Tanner staging: 344
treatment adherence: 344
HIV. Live with it. Get Tested: 342
homeless or runaway: 337
in foster care: 337
incarcerated: 337
injection drug users: 337
lesbian, transgender, and bisexual youth: 337
linking youth to care: 342
marijuana: 337
mental illness: 337, 346
physical exam, laboratory tests and immunizations: 343
physically abused: 337
prevention: 340
Project TREAT (treatment regimens enhancing adherence in teens): 344
safer sex: 342
sexual risk: 336
sexually abused: 337
socioeconomic risk: 338
substance use: 346
teen AIDER interview for HIV counseling, testing, and risk reduction: 340
Adult victimization: 296
Advanced HIV infection plus altered status: 132
Aegis: 473
African American culture: 282
case study: 284
Agenerase: 96 AIDS
Alliance for Children, Youth & Families: 474
AIDS Clinical Trials and Women: 476
AIDS Clinical Trials Group: 476
AIDS Clinical Trials Information Service (ACTIS): 476
AIDS dementia complex (ADC): 82, 119
AIDS Education and Training Centers Warmline: 472
AIDS risk reduction model, the: 48
AIDS Treatment Information Service (ATIS): 471
Alcohol: 140, 319, 330, 337
alcohol addiction: 325
alcohol use estimates by age, gender, and ethnicity in the U.S.: 315
Algorithms for diagnosis and management of symptoms: 124
Allergic/irritative reaction: 184
Alternative HIV tests: 84
Alternative or complementary therapy: 107
Alternatives to HRT: 188
Amenorrhea: 149
American College of Obstetricians and Gynecologists
(ACOG): 483
American Foundation for AIDS Research (AMFAR) Treatment Directory: 473
American Psychological Association Office on AIDS: 480
Americas: 22
AMHARN: See Adolescent Medicine HIV/AIDS Research Network
Amniocentesis: 241
Amprenavir: 96, 100, 246
Anemia: 123, 367
Anovulation: 151
Antepartum: 236
antepartum fetal surveillance/testing: 239
Antibiotic prophylaxis: 259
Antimicrobials
commonly used antimicrobials for the treatment and prevention of
opportunistic infections in HIV-infected patients: 413
Acyclovir (Zovirax®): 428
Aerosolized pentamidine: 425
Albendazole (Albenza®): 427
Amphotericin B (Fungizone®): 419
Atovaquone (Mepron®): 418
Azithromycin (Zithromax®): 414
Cidofovir (Vistide®): 430
Clarithromycin (Biaxin®): 415
Clotrimazole: 421
Dapsone: 427
Ethambutol (Myambutol®): 418
Famciclovir (Famvir®): 429
Fluconazole (Diflucan®): 421
Flucytosine (Ancobon®): 420
Foscarnet (Foscavir®): 430
Ganciclovir (Cytovene®): 429
Hydroxyurea (Hydrea®, Droxia®): 419
Interferon (Roferon®, Intron®): 431
Intravenous pentamidine: 426
Isoniazid (INH, Tubizid®, Nydrazid®): 416
Itraconazole (Sporanox®): 422
Nystatin: 420 Primaquine: 426
Pyrazinamide: 416
Pyrimethamine (Daraprim®): 423
Ribavirin (Rebetrol®): 431
Rifabutin (Mycobutin®): 417
Rifampin (Rifadin): 417
Sulfadiazine: 424
Trimethoprim-sulfamethoxazole (Bactrim, Septra,
Cotrim, Sulfatrim: 413
Valacyclovir (Valtrex®): 428
drug interactions of antimicrobials: 436
nonnucleoside reverse transcriptase inhibitors (NNRTIs): 439
Delavirdine (Rescriptor®) (DLV): 440
Efavirenz (Sustiva®) (EFV): 443
Nevirapine (Viramune®) (NVP): 439
nucleoside reverse transcriptase inhibitors (NRTIs): 436
3TC (lamivudine) (Epivir®): 438
Abacavir (Ziagen®): 438
AZT (zidovudine) (Retrovir®): 436
d4T (stavudine) (Zerit®): 438
ddC (zalcitabine) (Hivid®): 438
ddI didanosine) (Videx®): 436
protease inhibitors (PIs): 445
Amprenavir (Angenerase®) (APV): 459
Indinavir (Crixivan®) (IDV): 445
Lopinavir/ritonavir (LPV/r) (Kaletra®): 447
Nelfinavir (Viracept®) (NFV): 457
Ritonavir (Norvir®) (RTV): 452
Saquinavir (Invirase®) (Fortovase®) (SQV): 450
safety of commonly used antimicrobials: 432
Aminoglycosides: 433
Aztreonam: 434
Cephalosporins: 432
Chloramphenicol: 434
Clindamycin: 432
Erythromycin: 432
Fluoroquinolones: 433
Imipenem: 433
Meropenem: 433
Methenamine: 434
Metronidazole: 432
Nitrofurantoin: 434
Penicillins: 432
pregnancy risk factor: 435
Tetracyclines: 433
Vancomycin: 434
Antiretroviral agents: 94
hydroxyurea in combination with other antiretroviral drugs: 100
recommended antiretroviral agents for initial treatment of established HIV infection: 100
sites of action of antiretroviral agents: 94
Antiretroviral resistance: 396
Antiretroviral therapy: 93, 94
alternative/complimentary therapies: 402
benefits of antiretroviral drugs in pregnancy: 402
general principles: 93
in pregnancy: 106
recommendations for antiretroviral therapy in the treatment-experienced patient: 101
risks and benefits of early initiation of antiretroviral therapy: 106
St John’s wort: 402
Antiretroviral therapy in substance abusers: 329
Antiretroviral treatment: 241
antiretroviral pregnancy registry: 253
comparison of intrapartum/postpartum regimens
for HIV-Infected Women in Labor Who Have had
no prior antiretroviral therapy: 250
maternal adverse effects: 247
preclinical and cinical data relevant to use of antiretroviral drugs in pregnancy: 242
Antiretrovirals: 404
antiretroviral cocktail: 401
antiretroviral pregnancy registry, the: 401
nonnucleoside reverse transcriptase inhibitors (NNRTIs): 407
Delavirdine (Rescriptor®): 409
Efavirenz (Sustiva®): 407
Nevirapine (Viramune): 408
nucleoside reverse transcriptase inhibitors (NRTIs): 404
Abacavir (Ziagen®): 404
Didanosine (Videx, ddI): 405
Lamivudine, (Epivir, 3TC): 406
Stavudine (Zerit®, d4T): 405
Zalcitabine, (Hivid®; Dideoxycytidine, ddC): 407
Zidovudine (Retrovir®, AZT): 404
pharmacokinetics of antiretroviral drugs: 403
protease inhibitors (PIs): 409
Amprenavir (Angenerase®): 412
Indinavir (Crixivan®): 411
Lopinavir/Ritonavir (LPV/r) (Kaletra®): 409
Nelfinavir (Viracept®): 411
Ritonavir (Norvir®): 410
Saquinavir (Invirase® Fortovase®): 410
risks of antiretroviral drugs in pregnancy: 402
Aphthous genital ulcerations: 165
Aphthous ulcers: 82
Approach to the patient: 33
nonverbal communication: 34
ASCUS (atypical squamous cells of undetermined significance): 156
Asia: 22
Association of Nurses in AIDS Care (ANAC): 483
Aternative or complementary therapies: 36
Atrophic vaginitis: 173
Atypical glandular cells of undetermined significance: 158
Azole resistance: 169
AZT: See Retrovir, Zidovudine
B
A B
C D E F
G H I J
K L M N
O P Q R
S T U V
W X Y Z
Bacterial pneumonia: 79, 107
Bacterial vaginosis (BV): 6, 59, 60, 166, 226
recommended management: 167
Bad news, breaking: 367
mnemonic for breaking bad news: 368
Barrier contraceptives: 67
Bartholin’s abscess: 182
Baseline laboratory evaluation: 85, 91
Behavioral Intervention: 49
checklist for the behavioral intervention counseling session: 57
Behavioral intervention models: 48
Behavioral theories relevant to sexual risk reduction counseling: 48
Behcet’s syndrome: 164
Benefits of therapy: 98
Benign breast tumor: 186
Benign or malignant ovarian neoplasm: 178
Bereavement: 375
Bethesda System, Pap smear report format for: 156
Biologic and host-related factors affecting sexual transmission: 5
Biopsy: 181
Bisexual youth, lesbian, transgender, and: 337
Body fluids and risk of exposure requiring postexposure prophylaxis: 384
Branched DNA (bDNA): 84, 88
Breast cancer: 186
Breast lump: 185
breast tumor: 186
breast cancer: 186
fibrocystic change: 186
Breast-feeding: 236
BufferGel: 69
Bulletin of Experimental Treatments for AIDS (BETA): 476
C A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
C31G: 69
Cancer: 151
invasive cervical cancer in HIV disease: 154
Candida albicans (C. albicans): 167, 169
Candida vaginitis: 107
Candidiasis: 114
oral: 107
vaginal: 107
Caracas definition, HIV disease classification: 13
Care provider issues: 308
Case definition for AIDS among adults and adolescents: 9
CD4 lymphocyte count: 85
CDC: See Centers for Disease Control and Prevention
Centers for Disease Control and Prevention (CDC): 8, 72, 83
CDC guidelines: 71
Centers for Disease Control National Prevention Information Network: 473
Central Asia: 22
Central nervous system (CNS): 82
Central nervous system lymphoma: 121
Cervical cancer in HIV disease, invasive: 154
Cervical dysplasia: 154
Cervical ectopy: 6
Cervical lesions, management of: 158
Cervical testing: 152
Cervicitis: 82
Cesarean delivery: 235
Chancroid: 163
Checklist for the behavioral intervention counseling session: 57
Chemistry panels, hematology and: 89
Chickenpox: 89
Childhood sexual abuse: 296, 297
Children and adolescents: 143
Children of mothers at risk: 1
Chlamydia: 172
Chlamydia trachomatis: 69
Chronic diarrhea: 127
Chronic hepatitis B and C: 121
Classification system, 1993, revised, for HIV infection: 9
Clinical and psychosocial care, adolescents: 343
Clinical programs, multiservice: 301
CMV: See Cytomegalovirus CNS: See Central nervous system
Cocaine: 43, 140, 299, 314, 319, 320, 330
cocaine addiction: 325
cocaine use in pregnancy: 329
Coccidiomycosis: 253
Colonoscopy/sigmoidoscopy: 189
Colposcopy: 181
indications for: 157
Combivir: 95
Communication: 33
Community: 284
Community AIDS Treatment Information Exchange (CATIE): 477
Comorbidity related to substance abuse: 315
Complications correlation of complications with CD4 cell counts: 108
infectious: 108
noninfectious: 108
opportunistic diseases: 107
Complimentary therapies: 34, 107
Condoms: 217, 223, 233
acceptability of: 64
condom use: 61, 62
condoms and prevention of HIV infection: 61
factors associated with condom use and non-use: 66, 341
female condoms: 61, 63, 64, 218
insertion and positioning: 65
male condoms: 62, 217
postexposure prophylaxis (PEP): 69, 72
Condyloma acuminata: 82
Confidentiality: 35
Confidentiality and legal issues: 338
Congenital syphilis: 228
toxoplasmosis: 229
viral infection: 229
Containing the epidemic: 23
Contraception: 35, 214
barrier contraceptives: 67
contraception and prevention of HIV-1 infection: 68
contraception and prevention of infection are separate issues: 68
contraceptive methods: 215
cervical cap: 219
nonparous: 219
parous: 219
condom use: 261
depomedroxyprogestone acetate (DMPA): 216
diaphragm: 220
female sterilization: 221
hormonal methods: 214
IUD: 221
male sterilization: 222
nonbarrier: 6
Norplant: 216
oral contraceptives: 214
oral contraceptive pill: 215
progestin-only pill: 217
spermicides: 220, 223
hormonal contraceptives: 67
other forms of contraception and the risk of HIV infection: 67
Coping with HIV: the experience of HIV-positive Women in the context of their relationships: 290
Correctional systems: 142
Cough: 129
Counseling: 213
checklist for the behavioral intervention counseling session: 57
components of HIV pre- and posttest counseling: 45
counseling and support: 257
counseling the HCW: 394
ethnic and gender considerations in risk reduction counseling: 57
HIV and pregnancy counseling issues: 214
HIV counseling and testing: 44
impact of HIV counseling and testing on prevention: 47
practical aspects of counseling patients about sexual risk reduction: 52
pre- and posttest HIV counseling: 44
Counseling and education: 39
Counseling and testing, adolescents: 339
teen AIDER interview for HIV counseling, testing, and risk reduction: 340
Crack cocaine: 43, 299, 314, 319
Criminal justice settings: 330
Critical Path AIDS Project: 478
Crixivan: 96
Crohn’s disease: 164
Cryptococcal meningitis: 109, 115
Cryptococcus neoformans: 112
Cryptosporidiosis and microsporidiosis: 118
Crytococcosis:: 253
Cultural background: 33, 36
Cultural issues: 280
African American culture: 282
case study: 284
the seven Rs (core African American values): 282
African American women: 275, 278
interventions: 283
community: 284
interventions: 285
cultural considerations: 275
Hispanic culture: 280
case study: 281
colectivismo: 280
familismo: 280
interventions: 281
personalismo: 280
respeto: 280
simpatía: 280
Latina/Hispanic women: 275, 278
minority women: 275
spirituality: 283
Cytomegalovirus (CMV): 82, 89, 112, 117, 163, 229, 253
retinitis: 81
D A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Dame Cicely Saunders: 353
ddI: See Didanosine
Death: 373
grief and bereavement: 375
guidelines for after the death: 376
multiple loss: 375
Delavirdine: 95, 100, 243
Demographic comparison of HIV-positive women and men: 295
Department of Health and Human Services (DHHS): 97
panel on clinical practices for treatment of HIV infection: 97
Depomedroxyprogestone acetate (DMPA): 216
Depression: 140, 297
differential diagnosis of major depressive disorder: 304
Detoxification: 325
Developing AIDS, likelihood of: 87
Developing countries: 10, 20
Diaphragm: 220
Diarrhea
acute: 126
chronic: 127
Didanosine (ddI): 95, 242
Disclosure
to children: 37
to sexual partners: 37
Discrimination: 35
Disseminated histoplasmosis: 109
Disseminated Mycobacterium avium complex (MAC): 117, 253
DNA PCR: 84
Doctor-patient relationship: 141, 146
Domestic violence: 44, 45, 58, 213, 277, 278, 296
Douching: 60
Drug abuse: See Substance abuse
Drug addiction, defined: 313
Drug holiday: 101
Drug reaction: 165
Drug users, injection: 300
Drugs of special consideration in women: 463
Nonsteroidal antiinflammatory drugs (NSAIDs): 463
Acetaminophen: 463
Aspirin: 463
Methergine: 463
Narcotic analgesic: 463
Ritodrine: 463
Terbutaline: 463
DSM-IV drug addiction criteria: 320 Dysmenorrhea: 176
Dyspnea: 129, 365
E A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Early initiation of antiretroviral therapy in the asymptomatic patient, risks and benefits: 106
Eastern Europe: 22
Economic issues: 276
interventions: 276
poverty: 276, 277, 278, 285
Ecstasy (MDMA): 314
Ectopic pregnancy: 178
Education and counseling: 39
Education, patient: 144
Efavirenz: 95, 100, 243, 246
ELISA: See Enzyme-linked immunosorbent assay
Emotional milestones: the experience of the individual HIV-positive woman: 290; See also
Psychological issues, psychosocial issues, cultural issues) providing HIV care at emotional milestones: 291
Encephalopathy: 119
End-of-life care: See Palliative care
End-of-life issues: 371
advance care planning: 368, 370
advance directive: 370
care provider, care of the: 377
clinical treatment: 372
conversations for the end of life: 373
do not resuscitate: 372
goal setting: 368
grief and bereavement: 375
guidelines for after the death: 376
making plans: 369
multiple loss: 375
personal goals: 370
physical comfort: 371
physician’s card: 372
RPC (reassurance, presence, caring): 372
time of death: 374
Endometrial biopsy: 152
Endometrioma: 178
Endometriosis: 176
End-stage organ failure: 367
Enzyme-linked immunosorbent assay (ELISA): 46, 83, 84, 85
Epidemiology of HIV/AIDS: 1
Epivir: 95
Erythropoietin in the anemic HIV patient, guidelines for the use of: 122
Established infection: 14
Estrogen and progestin preparations, commonly used: 188
Ethnic and gender considerations in risk reduction counseling: 57
Evaluation baseline laboratory evaluation: 85, 91
initial: 78
Evaluation of the HIV-infected woman: 35
Examination: 81
cytomegalovirus (CMV) retinitis: 81
eyes: 81
general: 81
hepatosplenomegaly: 82
Kaposi’s sarcoma (KS): 81
lungs: 81
lymph nodes: 81
neurologic: 82
oropharynx: 81
pelvic: 82
skin: 82
Exposure: See Occupational exposure
Eyes: 81
F A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Factors associated with condom use and non-use: 66
Factors facilitating transmission: 4
Factors that influence rate of HIV disease progression: 18
Family issues: 277
Family-centered care: 38
Fatigue: 354
treatable causes of fatigue: 355
FDA Background on Protease Inhibitors: 473
Female condoms: 61, 63, 64
insertion and positioning: 65
Female sterilization: 221
Femidom, female condom: 64
Fertility, HIV and: 224
Fetal
fetal/infant adverse effects: 245
surveillance: 239
Fetal alcohol syndrome: 329
Fetal syphilis: 228
Fetal/maternal monitoring: 258
Fetal/neonatal factors: 235
Fever: 129
Fever of unknown origin: 125
Fibrocystic change: 186
Fibroids: See Uterine leiomyomas
5-fluorouracil (5-FU): 158
Flow sheet, patient intake: 92
Food-drug interactions: 463
Fortovase: 96
Frequency of visits: 257
Fungal infection: 183
G A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Gastrointestinal masses: 178
Gastrointestinal pathology: 177
Gender
Gender considerations in risk reduction counseling, ethnic and: 57
Gender differences: 363
Gender effects: 17
Genetic mutability: 93
Genital itching/irritation: 183
allergic/irritative reaction: 184
differential diagnosis and management: 183
evaluation: 183
fungal infection: 183
history: 183
pediculosis pubis: 185
physical exam: 183
scabies/lice: 184
Genital masses/nodules: 182
Bartholin’s abscess: 182
evaluation: 182
molluscum contagiosum: 182
tumors, other masses: 183
Genital tract infections: 59, 151
Genital ulcers: 159
aphthous genital ulcerations: 165
Behçet’s syndrome: 164
chancroid: 163
Crohn’s disease: 164
drug reaction: 165
evaluation: 159
granuloma inguinale: 164
hidradenitis Suppurativa: 164
inflammatory conditions: 164
lymphogranuloma venereum: 163
neoplastic: 165
syphilis: 161
trauma: 165
tuberculosis: 164
Genital warts: 180
biopsy: 181
colposcopy: 181
relation to HIV: 180
Genitalia/perineum: 82
Genotypic assays: 103
comparison of genotypic and phenotypic assays: 105
Global Impact: 21
Glucose intolerance: 96
Glucose-6-phosphate dehydrogenase (G6PD): 90
Goals of HIV disease management: 80
Gonorrhea: 43, 171
Granuloma inguinale: 164
Grief: 375
facilitating the grieving process: 377
Growth House Search Engine: 481
Guidelines CDC guidelines: 71
for care, HIV and reproduction: 236
antepartum: 236
antepartum fetal surveillance/testing: 239
history/physical examination: 236
laboratory evaluation in the HIV-infected pregnant woman: 237
laboratory examination by trimester: 237
for gynecologic referral: 190
for interaction with all patients: 33
for use of erythropoietin in the anemic HIV patient: 122
treatment guidelines: 97
USPHS/IDSA guidelines: 109
Gynecologic
exams: 33
history: 37
Gynecologic evaluation: 189
Gynecologic referral, guidelines for: 190
H A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
HAART: See Highly active antiretroviral therapy
Handbook for Palliative Care: 481
Harm reduction: 322
HCSUS: See HIV Cost and Services Utilization Study
HCW: See Health Care Worker
Headache: 131 Health belief model: 48
Health Care Financing Administration (HCFA): 474
Health care worker (HCW)
counseling the HCW: 394
HIV-seropositive HCW: 396
occupational exposure: 383
pregnant HCW: 396
Health Initiatives for Youth (HIFY): 479
Health maintenance issues: 189
gynecologic evaluation: 189
Pap smears: 189
sigmoidoscopy/colonoscopy: 189
STD screening: 189
Health Resources and Services Administration (HRSA): 343, 344, 349
Hematology and chemistry panels: 89
Hepatitis: 89
chronic hepatitis: 121
hepatitis A: 89, 112
hepatitis B: 89, 111
hepatitis B virus (HBV): 230
hepatitis C: 90
hepatitis C virus (HCV): 231
laboratory tests for: 90
Hepatosplenomegaly: 82
Heroin: 140, 314, 319, 330
Herpes simplex virus: 69
Herpes simplex virus (HSV): 82, 116, 159
genital herpes simplex: 226
recommended management: 161
Heterosexual contact: 2
Hiccups: 365
Hidradenitis suppurativa: 164
High-grade squamous intraepithelial lesion: 158
Highly active antiretroviral therapy (HAART): 1, 99, 139
High-risk sexual activity: 38
High-risk STDs: 43
Hispanic culture: 280
case study: 281
Hispanic women: 35
Histoplasma capsulatum: 112
Histoplasmosis: 82, 253
disseminated: 109
History, patient: 78
HIV
and cervical dysplasia: 154
behavioral risk, adolescent: 337
biological risk, adolescents: 337
heightened vulnerability for infection (adolescents): 337
HIV care for adolescents: 338
HIV treatment, adolescents: 344
invasive cervical cancer in HIV disease: 154
prevention, adolescents: 340
socioeconomic risk, adolescents: 338
HIV cost and services utilization study: 39, 141
HIV counseling and testing: 44
HIV Dent: 475
HIV disease progression
factors that influence rate of: 18
natural history and: 7
HIV encephalopathy: 82
HIV Medication Guide: 473
HIV pathogenesis: 80
HIV RNA level in tissues: 15
HIV RNA present in blood: 14
HIV therapies, adherence to: 139
HIV transmission: 3
biologic and host-related factors affecting sexual transmission: 5
factors facilitating transmission: 4
maternal/obstetric factors: 233
modes of: 3
parenteral transmission: 3
perinatal transmission: 4, 231
potential variables in transmission: 232
sexual transmission: 3
staging: See Highly active antiretroviral therapy (HAART)
susceptibility of the recipient: 6
transfusion-associated HIV transmission: 4
transmission risk: 4
HIV/AIDS: 1
epidemiology of: 1
HIV/AIDS Phone resources: 478
HIV/AIDS Project Development and Evaluation Unit (HAPDEU): 479
HIV-disease classifications
Caracas definition: 13
revised classification system for HIV infection, 1993: 9
Hivid: 95
Holiday, drug: 101
Home testing: 84
Homeless adolescents: 337
Homeless patients: 143
Hope: 369
Hormonal contraceptives: 67
Hormone replacement therapy (HRT): 187
alternatives to HRT: 188
Hospice: 349, 353
Host, infectiousness of the: 4
Host-related factors affecting sexual transmission, Biologic and: 5
Houston, Centers for Disease Control: 51
HPV: See Human papillomavirus
HRSA: See Health Resources and Services Administration
HRSA HIV/AIDS Bureau (HAB): 475
HRSA/CDC National Clinicians’ Post-Exposure Prophylaxis Hotline
(PEPline): 482
HRT: See Hormone replacement therapy
HSV: See Herpes simplex virus
Human papillomavirus (HPV): 82, 227
interrelationship of HIV and HPV and abnormal Pap smear: 153
Human relationship issues: 276
interventions: 278
Hydrosalpinx/pyosalpinx and tuboovarian abscess: 178
Hydroxyurea: 100, 246
Hyperlipidemia: 96
Hypertriglyceridemia: 96
I A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Identifying support systems and disclosure: 37
Illicit drug use: 299; See also Substance abuse injection drug users: 300
illicit drug use estimates by age, gender, and ethnicity in the U.S.: 314
Immune-based therapy: 107
Immunizations: 256
Immunizations, adolescents: 343
Immunosuppression, progressive: 93
Impact of HIV counseling and testing on prevention: 47
Improving adherence: 144
Incarcerated patients: 142
Indications for colposcopy: 157
Indications for consideration of change in therapy: 102
Indications for hospitalization in patients with
PID: 176
Indications for Initiation of Antiretroviral Therapy in the Chronically HIV-Infected Patient: 97
Indications for plasma HIV RNA testing: 88
Indicators and predictors. laboratory: 15
Indicators of prognosis and/or stage of illness: 16
Indinavir: 96, 100, 242, 246
Industrialized countries: 20
Infant feeding: 260
Infant, care of the HIV-exposed: 261
ARV treatment: 261
diagnosis of HIV: 261
Infection established infection: 14
primary or acute infection: 13
Infections, genital: 159
Infectiousness of the host: 4
Inflammatory conditions: 164
Influenza: 112
Initial evaluation: 78
Injection drug abuse: 1, 2, 3, 300, 320
Injection drug use: 1, 2, 3, 43, 300
Insomnia: 363
sleep problems (sample questionnaire for office use): 364
Integrated Regional Information Network: 483
Interaction with patients: 33
International Association of Physicians in AIDS Care
(IAPAC): 482
Interstitial cystitis: 179
Interval monitoring: 91
Interventions
African American cultural issues: 283
economic issues: 276
Hispanic cultural issues: 281
human relationship issues: 278
intervention models, behavioral: 48, 145
multifaceted: 144
psychological issues: 279
repetitive: 144
Intrapartum: 258
fetal/maternal monitoring: 258
intrapartum ARV prophylaxis: 259
universal precautions: 258
Invasive carcinoma: 158
Invasive cervical cancer in HIV disease: 154
Invirase: 96 IUD: 221
J A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Johns Hopkins University AIDS Service: 472
Joint UN Programme on AIDS (UNAIDS): 483
Journal of the American Medical Association: 475
K A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Kaiser Family Foundation (KFF): 475
Kaletra: 96
Kaposi’s sarcoma (KS): 81, 82, 107, 120
mucocutaneous KS: 107
KS: See Kaposi’s sarcoma
L A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Laboratory indicators and predictors: 15
Laboratory indicators of prognosis/stage of illness in HIV infection: 16, 17
Laboratory testing: 83
Laboratory tests: 152
Laboratory tests for hepatitis viruses: 90
Lack of therapeutic efficacy: 101
Lamiduvine: 242
Lamivudine
Lamivudine (3TC): 95
Language: 57
Latex male condoms: 62
Legal issues, confidentiality and: 338
Lesbian, transgender, and bisexual youth: 337
Level of education: 33
Life expectancy, factors associated with shortened: 367
advance care planning: 368, 370
advance directive: 370
maintaining hope: 369
making plans: 369
personal goals: 370
Likelihood of developing AIDS: 87
Lipid profile: 90
Lipodystrophy (fat redistribution syndromes): 96
Long-term nonprogressors: 17
Lopinavir: 96, 100, 243
Lopinavir/ritonavir: 96, 100, 243
Loss: 375
Lower extremity symptoms: 133
pain: 133
pain and numbness: 134
weakness and numbness: 133
Low-grade squamous intraepithelial lesion: 158
LSD: 314
Lungs: 81
Lymph nodes: 81
Lymphogranuloma venereum: 163
Lymphoma central nervous system: 121
systemic: 121
M A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
MAC: See Mycobacterium avium complex
maintaining hope: 369
Major depressive disorder, diagnosis of: 304
differential diagnosis of major depressive disorder: 304
Male condoms: 62
Male sterilization: 222
Malignancy, unresponsive: 367
Mammography: 189
Marijuana: 299, 314, 337
Measures to reduce STDs: 60
Measuring adherence: 143
Medical conditions: 151
Medical evaluation: 37
Medication toxicity: 101
Medications: 152
Men who have sex with men (MSM): 2
Meningitis, cryptococcal: 109, 115
Menopause: 187
commonly used estrogen and progestin preparations: 188
hormone replacement therapy (HRT): 187
alternatives to HRT: 188
Mental illness: 213, 277, 278, 346
mental illness in HIV-positive adolescents: 346
Microbicide products: 69, 72
Microsporidiosis, cryptosporidiosis and: 118
Minority women: 275
Mitochondrial toxicity: 247
Mittelschmerz: 177
Molluscum contagiosum: 82, 182
Monitoring the activity of HIV disease: 80
Monogamy: 41
Mucocutaneous KS: 107
Multidisciplinary medical collaborations: 35
Multiservice clinical programs: 301
common clinical issues for HIV-positive women: 301
common clinical misperceptions regarding psychiatric issues: 303
Mutability, genetic: 93
Mutations associated with resistance to specific agents: 104
Mycobacterium avium complex (MAC): 81, 111, 255
disseminated: 117
Mycobacterium tuberculosis: 110, 254
N A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
N-9: See Nonoxynol-9
NASBA: See Nucleic acid sequence-based amplification
National AIDS Clearinghouse: 481
National Clearinghouse for Alcohol and Drug Information
(NCADI): 481
National Clearinghouse on Child Abuse and Neglect Information: 480
National directory of state and local hotlines: 480
National Domestic Violence Hotline: 480
National Household Survey on Drug Abuse (NHSDA): 313
National Institute of Health (NIH): 343
National Institutes of Mental Health (NIMH): 49, 50
National Library of Medicine (NLM): 475
National Maternal and Child Health Clearinghouse: 476
National Pediatric & Family HIV Resource Center
(NPHRC): 474
Natural history and HIV disease progression: 7
Natural history of HIV: 80, 86
Natural lactobacilli: 69
Neisseria gonorrhoeae: 171
Nelfinavir: 96, 100, 243
Neoplastic: 165
Neuropathy, peripheral: 119
Neurosyphilis: 82
Nevirapine: 95, 100, 243, 250
New Jersey Women and AIDS Network: 477
New York Online Access to Health (NOAH): 474
NIAID Database for Anti-HIV Compounds: 473
NIH: See National Institutes of Health
NIMH (National Institutes of Mental Health): 49
NNRTIs: See Nonnucleoside reverse transcriptase inhibitors
Nonadherence: 33, 37
patient factors associated with nonadherence: 141
reasons patients cte for missing medication: 142
Nonbarrier contraceptive methods: 6
Non-Hodgkin’s lymphoma: 107
Nonnucleoside reverse transcriptase inhibitors (NNRTIs): 95, 139, 407, 439
Nonoccupational HIV Exposure Guidelines: 481
Nonoxynol-9 (N-9): 67, 69, 72
Nonprogressors, long-term: 17
Norplant: 216
Norvir: 96
NRTIs: See Nucleoside analogue reverse transcriptase inhibitors
Nucleic acid amplification: 84
Nucleic acid sequence-based amplification (NASBA): 84, 88
Nucleoside analogue reverse transcriptase inhibitors
(NRTIs): 94, 95
Nucleoside analogues: 94
Nucleoside reverse transcriptase inhibitors (NRTIs): 404, 436
O A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Occupational exposure: 383; See also Postexposure prophylaxis
antiretroviral resistance: 396
baseline and follow-up testing: 393
body fluids and risk of exposure requiring postexposure prophylaxis: 384
characteristics of injuries sustained by case patients and controls: 390
counseling the HCW: 394
determining the need for HIV postexposure prophylaxis after an occupational exposure: 386
exposure associated with transmission: 383
exposure evaluation: 393
exposure site management: 393
HIV infection following occupational exposure: 392
logistic-regression analysis of risk factors for HIV transmission
after percutaneous exposure to HIV-infected blood: 389
personal protective equipment: 391
postexposure management: 393
pregnant HCW: 396
preventing occupational exposure: 391
source patient evaluation: 393
U.S. health care workers with documented and possible
occupationally acquired HIV infection and AIDS: 384
Odynophagia: 135
Open-ended questions: 43
Opiate addiction: 324, 329
Opioid analgesics: 360
dose equivalents for opioid analgesics in opioid-naive adults and children: 362
opioid analgesic side effects: 360
opioid conversions: 361
Opportunistic diseases: 107
complications: 107
prophylaxis to prevent opportunistic disease: 110
Opportunistic infection prophylaxis: 109, 253
Opportunistic infections (OIs): 107
Opportunistic infections and primary prophylaxis in pregnant women: 254
Oral candidiasis: 79, 81, 107, 108, 115
Oral hairy leukoplakia: 107
Organ failure, end-stage: 367
Oropharynx: 81
Orphans: 22
Ovarian benign or malignant ovarian neoplasm: 178
functional cyst: 178
ruptured/hemorrhagic ovarian cyst: 176
torsion: 176
Ovarian functional cyst: 178
Oxford Textbook of Palliative Medicine: 481
P A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Pain: 173, 356
barriers to pain management: 357
barriers to pain relief: 357
mnemonic for assessment of pain: 359
pain intensity scales: 354
pain management with a history of substance abuse: 361
pharmacologic approaches to pain Management: W.H.O. three-step ladder: 358
principles of pain management: 358
Palliative care
advance care planning: 368, 370
advance directive: 370
care provider, care of the: 377
common symptoms in HIV disease: 352
goal setting: 368
hospice: 349, 353
in HIV disease: 350
quality of life: 350
W.H.O. definition: 349
Pan American Health Organization (PAHO): 13
Caracas definition, HIV disease classification: 13
Panos Institute: 483
Pap smear: 37, 91, 152, 153, 189
abnormal Pap smear: 153
ACGUS (atypical glandular cells of undetermined significance): 157
ASCUS (atypical squamous cells of undetermined significance): 156
Pap smear report format for Bethesda System: 156
recommendations for pap smear screening and
colposcopy: 156
single Pap smear: 155
suggested frequency of Pap smears: 157
Parenteral transmission: 3
Partnership: 33
Pathogenesis, HIV: 80
Patient history: 78
Patient intake flow sheet: 92
Patient’s age: 33
Patients
children and adolescents: 33, 143
education: 144
homeless: 143
incarcerated: 142
PCP: See Pneumocystis carinii pneumonia
Pediatric AIDS Clinical Trials: 476
Pediatric classification system: 262
Pediculosis pubis: 185
Pelvic examination: 37, 38, 82
Pelvic inflammatory disease: 82
Pelvic inflammatory disease (PID): 174
indications for hospitalization in patients with PID: 176
PID in the HIV-positive woman: 175
Pelvic mass: 177
benign or malignant ovarian neoplasm: 178
differential diagnosis: 178
ectopic pregnancy: 178
endometrioma: 178
evaluation: 177
gastrointestinal masses: 178
history: 177
hydrosalpinx/pyosalpinx and tuboovarian abscess: 178
ovarian functional cyst: 178
physical exam: 177
retroperitoneal lymphadenopathy: 178
uterine leiomyomas (fibroids): 178
Pelvic ultrasound: 152
Pelvic/abdominal pain: 173, 353, 359
acute pain: 173
chronic pain: 173
cyclic pain: 173
dysmenorrhea: 176
endometriosis: 176
evaluation: 174
gastrointestinal pathology: 177
history: 173
medication-related: 177
mittelschmerz: 177
ovarian torsion: 176
pelvic inflammatory disease (PID): 174
indications for hospitalization in patients with PID: 176
PID in the HIV-positive woman: 175
physical exam: 173
pregnancy: 174
ruptured/hemorrhagic ovarian cyst: 176
urinary tract pathology: 177
uterine leiomyomas (fibroids): 176
PEP: See Postexposure prophylaxis Perimenopause: 151
Perinatal HIV prevention: 482
Perinatal transmission: 4
Peripheral neuropathy: 82, 119
Phenotypic assays: 103
comparison of genotypic and phenotypic assays: 105
PHS Guidelines for the Management of Health Care Worker Exposures to HIV and Recommendations for Post Exposure Prophylaxis: 482
Physical examination: 81
Plasma HIV RNA: 84 indications for plasma HIV RNA testing: 88
Pneumocystis carinii pneumonia (PCP): 81, 107, 108, 110, 114, 146, 253, 254, 263
Pneumonia bacterial pneumonia: 79, 107
Pneumocystis carinii pneumonia (PCP): 81, 107, 108, 110, 114, 146, 253, 254, 263
Polyurethane male condoms: 62
Postexposure prophylaxis (PEP): 69, 71, 72, 106, 385
basic and expanded postexposure prophylaxis regimens: 385
determining the need for HIV postexposure prophylaxis after an occupational exposure: 386
postexposure prophylaxis (PEP): 395
Postpartum: 260
Posttest HIV counseling, pre- and: 44
components of HIV pre- and posttest counseling: 45
Poverty: 58, 294;
See also Economic issues socioeconomic risk: 338
Power of attorney: 369
Practical aspects of counseling patients about sexual risk reduction: 52
Predictors of adherence: 140
Predictors. laboratory indicators and: 15
Pregnancy: 144, 151
adverse pregnancy outcomes and relationship to HIV infection: 225
alternative/complimentary medication to avoid in pregnancy: 464
amniocentesis: 241
antibiotic prophylaxis: 259
antiretroviral pregnancy registry, the: 401
antiretroviral therapy in pregnancy: 106
antiretroviral treatment: 241
antiretroviral pregnancy registry: 253
comparison of intrapartum/postpartum regimens for HIV-infected
women in labor who have had no prior antiretroviral therapy: 250
maternal adverse effects: 247
preclinical and cinical data relevant to use of antiretroviral drugs in pregnancy: 242
bacterial vaginosis (BV): 226
benefits of antiretroviral drugs in pregnancy: 402
care of the HIV-exposed infant: 261
ARV treatment: 261
diagnosis of HIV: 261
CD4 count and HIV RNA levels in: 224
cesarean delivery: 235
chorionic villus sampling: 241
clinical course of HIV in: 225
contraception/condom use: 261
counseling and support: 257
counseling issues: 214
ectopic pregnancy: 178
effect of HIV on pregnancy course and outcome: 225
effects on HIV Infection: 224
fetal surveillance: 239
frequency of visits: 257
general principles for antiretroviral treatment in: 248
general principles for antiretroviral treatment in pregnancy: 248
genital herpes simplex: 226
guidelines for care: 236
antepartum: 236
antepartum fetal surveillance/testing: 239
history/physical examination: 236
laboratory evaluation in the HIV-infected pregnant woman: 237
laboratory examination by trimester: 237
hepatitis A vaccine: 231
hepatitis B virus (HBV): 230
hepatitis C virus (HCV): 231
human papillomavirus: 227
interaction of drugs with pregnancy-related side effects/physiologic changes: 248
intrapartum: 258
fetal/maternal monitoring: 258
intrapartum ARV prophylaxis: 259
universal precautions: 258
vaginal cleansing: 260
long-term follow-up of mother and infant: 261
mitochondrial toxicity: 247
mode of delivery: 258
opportunistic infections and primary prophylaxis in pregnant women: 254
percutaneous umbilical blood sampling: 241
perinatal transmission: 231, 244
breast-feeding: 236
fetal/neonatal factors: 235
maternal/obstetric factors: 233
potential variables in transmission: 232
postpartum: 260
assess healing: 260
care for mother and infant: 260
infant feeding: 260
pregnancy test: 152
pregnancy testing: 223, 224
preterm delivery: 246
reduction of secondary risk factors: 257
risks of antiretroviral drugs in pregnancy: 402
substance abuse in pregnancy: 329
syphilis: 228
treatment in: 106
ultrasound: 240
vulvovaginal candidiasis: 226
zidovudine perinatal transmission prophylaxis regimen: 248
Pregnant HCW: 396
Preventing spread of HIV: 80
Prevention
Prevention of HIV infection, condoms and: 61
Primary or acute infection: 13
Principles of HIV treatment: 80
Progestin preparations, commonly used Estrogen and: 188
Prognosis: 366
Progressive immunosuppression: 93
Progressive multifocal leukoencephalopathy: 82, 121
Project Inform: 477
Project RESPECT: 49, 50, 51, 54
Project TREAT (treatment regimens enhancing adherence in teens): 344
Prophylaxis to prevent opportunistic disease: 110
Prophylaxis, postexposure: 106
Protease inhibitors: 139
Protease inhibitors (PIs): 96, 409, 445
Pruritus: 364
Psychiatric disorders: 302
Psychiatric issues, common clinical misperceptions regarding: 303
Psychiatric medications, common: 307
Psychological issues: 278; See also Common clinical issues for HIV-positive women; Emotional milestones
interventions: 279
Psychopharmacology for the HIV-positive woman: General Guidelines: 305
Psychosocial issues: 275; See also Emotional milestones
adolescents: 343, 345
PWA Health Group: 478
Q A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Quality of life: 350
Quantitating symptoms: 353
Quantitative virology: 88
R A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Rape: 297
Rapid tests: 46, 47, 84
Reasoned action, theory of: 48
Reasons patients cite for missing medication: 142
Recipient, susceptibility of the: 6
Recipients of blood/blood products: 1
Recommendations antiretroviral agents for initial treatment of established HIV infection: 100
for antiretroviral therapy in the treatment-experienced patient: 101
for initial treatment regimens: 99
Recovering from the loss of a loved one to AIDS: 481
Recurrent candidiasis: 170
Reduction of secondary risk factors: 257
Referral to other services: 45
Regional HIV/AIDS statistics and features: 2
Relationships, coping with HIV: the experience of HIV-positive women in the context of their: 290
Renal/ureteral stones: 179
Reproductive concerns: 35
Rescriptor: 95
Resistance mutations: 474
Resistance testing: 103
Resources: 471
Respect: 34
Retroperitoneal lymphadenopathy: 178
Retrovir: See Zidovudine (ZDV)
Revised classification system for HIV infection, 1993: 9
Risk individual risk assessment: 42
individualized discussion of risk and risk-reduction: 44, 45, 46, 56
risk assessment for STD/HIV infections: 42
risk factors for HIV infection: 43
risk assessment for STD/HIV for women: 43
risk reduction topics: 53
risk-reduction plan: 45, 46, 56
teen AIDER interview for HIV counseling, testing, and risk reduction: 340
Risk factors for occupational HIV transmission: 388
body fluids and risk of exposure requiring postexposure prophylaxis: 384
logistic-regression analysis of risk factors for HIV transmission
after percutaneous exposure to HIV-infected blood: 389
magnitude of risk: 388
personal protective equipment: 391
preventing occupational exposure: 391
U.S. health care workers with documented and possible
occupationally acquired HIV infection and AIDS: 384
Risk of progression to AIDS-defining illness: 98
Risks and benefits of early initiation of antiretroviral therapy: 106
Ritonavir: 96, 100, 243
Rs, the seven (core African American values): 282
reason: 282
reciprocity: 282
reconciliation: 282
respect: 282
responsibility: 282
restraint: 282
reverence: 282
RT-PCR (reverse transcriptase polymerase chain reaction): 84, 88
Runaway adolescents: 337, 340
Ruptured/hemorrhagic ovarian cyst: 176
S A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Safe sexual practices: 35, 277
Saliva test: 85
San Antonio, University of Texas: 51
Saquinavir: 96, 100, 242
Saunders, Dame Cicely: 353
Scabies/lice: 184
Screening strategies: 44
Seattle Treatment Education Project (STEP): 478
Seborrheic dermatitis: 82
Self-efficacy: 141
Self-esteem: 277, 278
Sensitivity: 34
Serology: 83, 89
Sex: 42
abstinence: 41, 72
discussing sex: 42
unprotected sex: 42
Sexual abuse childhood sexual abuse: 296, 297, 336
Sexual history: 43
Sexual transmission: 3
biologic and host-related factors affecting sexual transmission: 5
Sexually transmitted diseases (STDs): 41, 158
and pregnancy: 336
behavioral risk, adolescent: 337
biological risk, adolescents: 337
concerns or symptoms of STDs: 45
exposure to: 38
gonorrhea: 43
heightened vulnerability for infection (adolescents): 337
high-risk STDs: 43
in adolescents: 337
measures to reduce STDs: 60
monogamy: See Enzyme-linked immunosorbent assay prevention: 340
risk assessment for STD/HIV for women: 43
risk assessment for STD/HIV infections: 42
sexually transmitted diseases and the risk of HIV infection: 59
screening: 38
socioeconomic risk, adolescents: 338
STD prevention: 69
STD screening: 38, 91
syndromic management of STDs: 59
syphilis: 43, 228
Shingles: 82, 89, 107
Sigmoidoscopy/colonoscopy: 189
Simian immunodecficiency virus: 70
Single Pap smear: 155
Sites of action of antiretroviral agents: 94
Skin: 82
Sleep disturbance: 363
sleep problems (sample questionnaire for office use): 364
Slim disease: See Wasting syndrome Social cognitive theory: 48
Societal inequalities: 58
Spermicides: 220, 223
Spirituality: 36, 283, 374
spiritual assessment: 374
St John’s wort: 402
Stage of change (SOC) behavioral theory: 48
Stage of illness, indicators of prognosis: 16
Stages of change theory: 48
Staging of HIV: 8
Stavudine: 100, 242
Stavudine (d4T): 95 STDs: See sexually transmitted diseases
Sterilization: 68
Stigmatization: 35
Streptococcus pneumoniae: 111
Sub-Saharan Africa: 21, 22
Substance abuse: 151, 277, 278, 313
active: 140
addiction severity index (ASI): 320
alcohol: 140, 319, 330
alcohol addiction: 325
alcohol use estimates by age, gender, and ethnicity in the U.S.: 315
antiretroviral therapy: 329
CAGE survey: 318
clues to substance use: 318
cocaine: 43, 140, 314, 319, 320, 330
cocaine use in pregnancy: 329
cocaine addiction: 325
comorbidity related to substance abuse: 315
crack cocaine: 314, 319
crack cocaine use: 43
detoxification: 325
diagnosis: 318, 320
drug addiction, defined: 313
DSM-IV drug addiction criteria: 320
duration of drug detection: 321
ecstasy (MDMA): 314
epidemiology: 314
gamma-hydroxybutyrate: 314
heroin: 140, 314, 319, 330
identification: 318
illicit drug use estimates by age, gender, and ethnicity in the U.S.: 314
impact of societal perceptions and beliefs: 317
in HIV-positive adolescents: 346
in pregnancy: 329
in women: 317
injection drug abuse: 43, 320
ketamine: 314
LSD: 314
marijuana: 314
medical conditions and sequelae associated with substance use: 315
methamphetamine: 314
opiate addiction: 324, 329
pain management with a history of substance abuse: 361
prevalence of drug use: 314
rohypnol: 314
treatment of substance abuse: 322
cognitive/behavioral interventions: 326
components of drug use treatment: 323
new pharmacologic approaches: 326
nonpharmacologic drug addiction treatments: 327
pharmacologic interventions: 323
predictors of drug treatment retention and the durability
of treatment gains: 327
relapse: 328
treatment programs: 322
treatment readiness and harm reduction: 322
12-step programs: 327
urine testing: 321
withdrawal: 319
Suggested frequency of Pap smears: 157
Suicide risk, evaluation of: 307
risk factors and considerations in the evaluation of suicide risk: 308
Surfactants: 69
Surviving with HIV: contemporary HIV-positive women in their context of poverty, sexual abuse, and drugs: 294
Susceptibility of the recipient: 1, 6
Sustiva: 95
Symptoms: 353
common symptoms in HIV disease: 352
management of individual symptoms: 354
quantitating symptoms: 353
Syndromic management of STDs: 59
Syphilis: 43, 82, 89, 161, 228
congenital syphilis: 228
fetal syphilis: 228
recommended management: 162
System of care: 142, 146
Systemic lymphoma: 121
T A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Tanner staging: 344
Team approach: 35
Teen AIDER interview for HIV counseling, testing, and risk reduction: 340
Terry Beirn Community Programs for Clinical Research on AIDS
(CPCRA): 476
Testing
alternative tests: 84
enzyme-linked immunosorbent assay (ELISA): 83
HIV counseling and testing: 44
home testing: 84
impact of HIV counseling and testing on prevention: 47
indications for plasma HIV RNA testing: 88
laboratory: 83
laboratory tests for hepatitis viruses: 90
rapid tests: 46, 84
resistance testing: 103
saliva test: 85
urine test: 85
western blot: 83, 84, 85
Testing, counseling and, adolescents: 339
laboratory tests: 343
teen AIDER interview for HIV counseling, testing, and risk reduction: 340
Theory of reasoned action: 48
Therapeutic efficacy, lack of: 101
Therapy alternative or complementary therapy: 107
antiretroviral: 93, 94
general principles: 93
benefits of: 98
efficacy, lack of: 101
immune-based therapy: 107
indications for consideration of change in therapy: 102
Thrush: See Oral candidiasis Time course: 15
Toxicity medication: 101
Toxoplasmic encephalitis: 253
Toxoplasmosis: 89, 109, 116, 229, 253, 255
congenital: 229
toxoplasma gondii: 89, 111, 255
Transfusion-associated HIV transmission: 4
Transgender, lesbian, and bisexual youth: 337
Transmission of HIV: See HIV Transmission
Trauma: 165
Treatment accute HIV infection, treatment of: 105
adherence, 33
adherence, adolescents: 344
adherence: using your EARS: 345
guidelines: 97
pregnancy, treatment in: 106
recommendations for initial treatment regimens: 99
recommended antiretroviral agents for initial treatment of established HIV infection: 100
TREAT (treatment regimens enhancing adherence in teens): 344
Treatment adherence: 33
Trichomoniasis: 170
Trimethoprim-sulfamethoxazole (TMP-SMX): 114
Truth, telling the: 367
Tuberculosis (TB): 82, 90, 107, 118, 164
Tumors: 179
Tumors, other masses: 183
12-step programs: 327
U A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
U.S. health care workers with documented and possible occupationally acquired HIV infection and AIDS: 384
Ulcers
aphthous: 82
genital ulcers: 159
Ultrasound: 240
University of California: 50
University of California at San Francisco: 472
University of San Francisco HIVInSite Adherence Resources: 479
University of Texas: 50
Unprotected sex: 42
Unresponsive malignancy: 367
Urethral syndrome: 179
Urinary
urinary symptoms: 178
differential diagnosis and management: 179
evaluation: 179
history: 178
interstitial cystitis: 179
physical exam: 178
renal/ureteral stones: 179
tumors: 179
urethral syndrome: 179
urinary incontinence: 180
urinary retention: 180
urinary tract infection (UTI): 179
urinary tuberculosis: 179
urinary tract pathology: 177
Urine test: 85
USPHS/IDSA guidelines: 109
Uterine leiomyomas (fibroids): 151, 176, 178
V A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Vaccines: 69, 70, 72
Vaginal cleansing: 260
Vaginal discharge: 82, 107, 166
bacterial vaginosis (BV): 166
differential diagnosis and management: 166
evaluation: 166
history: 166
physical exam: 166
Vaginitis: 82
atrophic vaginitis: 173
azole resistance: 169
C. albicans: 169
candidiasis: 107, 167, 169, 226
chlamydia: 172
foreign body: 173
gonorrhea: 171
local irritants: 173
pelvic/abdominal pain: 173
recommended management: 168
recurrent candidiasis: 170
trichomoniasis: 170
Varicella-zoster virus (VZV): 82, 89, 111
Videx: 95, 242
Viracept: 96
Viral detection: 84
isolation: 84
properties: 7
replication: 93
set point: 14
viral load assays: 88
viral load, adherence and: 140
Virammune: 95
Visual materials: 57
Vulvovaginal candidiasis: 107, 226
Vulvovaginitis: See Vaginitis
W A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Wasting syndrome (slim disease): 119, 367
Western blot: 45, 46, 83, 84, 85
Withdrawal: 319
Women alive: 477
Women Organized to Respond to Life-threatening Disease (WORLD): 477
Women’s Experiences: An International Perspective: 483
World Health Organization (W.H.O.): 10, 46
clinical HIV staging system and proposed modifications, the: 11, 12
three-step ladder: 360
X A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Xerostomia: 365
Y A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Yeast vaginitis: 60
Z A
B C D E F
G H I J K
L M N O P
Q R S T U
V W X Y Z
Zalcitibine (ddC): 95, 242
ZDV: See Zidovudine
Zerit: 95 Ziagen: 95
Zidovudine (ZDV): 71, 95, 242
for postexposure prophylaxis: 385, 388
safety of ZDV exposure: 245
ZDV and nevirapine: 251
ZDV carcinogenicity: 245
ZDV/3TC: 250
zidovudine perinatal transmission prophylaxis regimen: 248
|